Secukinumab, an IL-17A inhibitor, has shown clinical efficacy in patients with moderate-to-severe plaque psoriasis.<h4>Aims</h4>To test the clinical efficacy and safety of secukinumab in a paediatric patient with ATP-binding cassette subfamily A member 12 deficiency-related severe erythrodermic ARCI.<h4>Materials & methods</h4>6-months therapeutic trial. Here, IL17A is linked to psoriasis vulgaris.